2014

March:
Vigilant Closes $2.3 Million Initial Round of Financing


February:
• Leading industry recognized in vitro diagnostic expert, Robert C. Bohannon, Ph.D.,
joins Vigilant to lead the company's product development efforts.


2013

November:
• Vigilant strengthens its management team with the addition of John Comisi, D.D.S., M.A.G.D.
as Chief Dental Officer and Robert Hamilton, C.P.A. as Chief Financial Officer.


September:
Vigilant highlighted at Project Lift Miami and HealthTech Showcase 2013


July:
Jonathan “Jack” Lord, M.D., Named to Vigilant Board of Directors


April:
Study Shows Vigilant’s Simple “Rinse and Spit” Test Effective in Detecting Oral Cancer


2012

October:
Vigilant Biosciences Completes Feasibility Clinical Study of New “Rinse and Spit” Oral Cancer Test


May:
VigilantBIO highlighted as a success story as a University of Miami spin-off.


March:
VigilantBIO wins Association of University Technology Managers (AUTM) VentureForum
competition.


February:
VigilantBIO selected to round of "Sweet 16" for 3rd annual Cade Museum Prize competition.


January:
VigilantBIO announces its first issued patent for key oral cancer biomarker detection claims
as part of overall licensed portfolio from University of Miami.


VigilantBIO selected as finalist for second annual AUTM Venture Forum competition.

2011

October:
• Notice of Allowance received from U.S. Patent and Trademark office for key claims to
salivary biomarker technology exclusively licensed to Vigilant Biosciences.

• Seasoned business executive and dental industry veteran joins Vigilant Biosciences
Board of Directors.


September:
• Research relating to University of Miami biomarker technology exclusively licensed to Vigilant
Biosciences presented at 2011 Annual Meeting of American Association of Cancer Research in
Washington, D.C.

• Henry Grage joins Vigilant Biosciences as Chief Technology Officer.


June:
• Serial entrepreneurs and accomplished life science executives Jeffrey Marrazzo and
Eric Stone join Board of Directors.


May:
• Vigilant Biosciences secures exclusive license to HNSCC biomarker intellectual property from
University of Miami.


January:
• Vigilant Biosciences founded by Matthew H.J. Kim, J.D., a corporate intellectual property attorney
and serial entrepreneur, with a vision to develop innovative and effective products to enable early
intervention to improve health and modify potentially adverse health outcomes.